Abstract

The invention provides an attenuated Salmonella vaccine vector comprising one or more heterologous polynucleotides that encode immunogenic Chlamydial peptides. In one embodiment, the attenuated Salmonella vaccine vector comprises aroC and ssaV attenuating mutations. The heterologous polynucleotides encoding the immunogenic Chlamydial peptides can be under the control of an inducible promoter such as a Salmonella ssaG …

Legal parties

Party
Inventors (applicants): Michael Joseph Lacy, Jonathan Lewis Telfer, Mark Richard Redfern
Agents: Cooley LLP (attorney)

The application was examined by Rodney P. Swartz (USPTO dept. 1645)

Claims

  • 1. An attenuated Salmonella microorganism comprising i) an attenuating mutation in a Salmonella Pathogenicity Island …
  • 2. The attenuated Salmonella microorganism of claim 1 , wherein said attenuated Salmonella microorganism induces …
  • 3. The attenuated Salmonella microorganism of claim 1 , wherein the second gene is a Salmonella …

Cited documents

Patents

  • WO WO 9806428, Feb. 1, 1998
  • Holdon US 2008/0175866 A1, Jul. 1, 2008
  • Crooke US 6846667 B1, Jan. 1, 2005
  • Crowl US 4582800 A, Apr. 1, 1986
  • Stocker US 4837151 A, Jun. 1, 1989
  • Holden US 6015669 A, Jan. 1, 2000
  • Popoff et al. US 5618666 A, Apr. 1, 1997
  • WO WO 0132697, May. 1, 2001
  • Feldman US 7211264 B2, May. 1, 2007
  • Holden US 2006/0216309 A1, Sep. 1, 2006
  • Stalker US 4810648 A, Mar. 1, 1989
  • WO WO 0185772, Nov. 1, 2001
  • WO WO 9835562, Aug. 1, 1998
  • WO WO 0014240, Mar. 1, 2000
  • Crooke US 7449178 B2, Nov. 1, 2008
  • Stocker US 4550081 A, Oct. 1, 1985
  • Haefliger US 6251406 B1, Jun. 1, 2001
  • Weissmann US 4530901 A, Jul. 1, 1985
  • Hensel US 2004/0203039 A1, Oct. 1, 2004
  • Goeddel et al. US 4766075 A, Aug. 1, 1988
  • Clarke US 6951732 B2, Oct. 1, 2005
  • WO WO 9617951, Jun. 1, 1996
  • WO WO 9611708, Apr. 1, 1996
  • WO WO 9945120, Sep. 1, 1999
  • Hensel et al. US 6936425 B1 / 435/7.1, Aug. 1, 2005
  • WO WO 9718225, May. 1, 1997
  • WO WO 9220805, Nov. 1, 1992
  • WO WO2008/156729, Dec. 1, 2008
  • Kleanthous US 6585975 B1, Jul. 1, 2003
  • EP 0889120, Jan. 1, 1999
  • Griffais et al. US 2006/0234260 A1, Oct. 1, 2006
  • WO WO00/14240, Mar. 1, 2000
  • WO WO 9901473, Jan. 1, 1999
  • Holden US 6984490 B1, Jan. 1, 2006
  • Rutter US 4440859 A, Apr. 1, 1984
  • Feldman US 6756042 B1, Jun. 1, 2004
  • Toole US 4757006 A, Jul. 1, 1988
  • Lam US 5397697 A, Mar. 1, 1995
  • Mark US 4677063 A, Jun. 1, 1987
  • Murray US 4710463 A, Dec. 1, 1987
  • WO WO 9310246, May. 1, 1993
  • Stocker US 5210035 A, May. 1, 1993
  • Hensel et al. US 2008/0075739 A1, Mar. 1, 2008
  • Hung US 5643579 A, Jul. 1, 1997
  • WO WO 03044047, May. 1, 2003
  • Nielsen US 5356797 A, Oct. 1, 1994
  • Holden US 6342215 B1, Jan. 1, 2002
  • Itakura US 4704362 A, Nov. 1, 1987
  • Haeflinger US 6458368 B1, Oct. 1, 2002
  • Jackson et al. US 2005/0048557 A1, Mar. 1, 2005

Description of the Figures

FIG. 1 shows a vector map of the pMBS vector map (with CT84 insert) and the nucleic acid sequence around the cloning site. FIG. 2 shows a vector map of suicide …

Description

Description of the Text File Submitted Electronically

The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename: EMER — 008 — 01US_SeqList_ST25.txt …

Other Patent Relations

This application is a national stage filing of PCT/US2009/047542 filed Jun. 16, 2009, which claims priority to U.S. Provisional Application No. 61/118,204 filed Nov. 26, 2008, and PCT/US2008/007490 filed Jun. …

Detailed Description of the Invention

General Description The invention provides live attenuated Salmonella microorganisms capable of expressing Chlamydial antigens, vaccine compositions, and methods of preventing and treating Chlamydial infection and related conditions. In particular, the live …

More details about Salmonella Vectored Vaccines Against Chlamydia and Methods of Use

Miscellaneous patent data

The invention is titled Salmonella Vectored Vaccines Against Chlamydia and Methods of Use, the application was published on Jun. 16, 2009, the known agent's organization is Cooley LLP, developed by Jonathan Lewis Telfer et al., similar classification categories are Attached to lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell; derivative thereof, N-Vinyl-2-pyrrolidone, UV protectant, characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, Bacillus, Elemental sulfur containing, Polymers containing halogen, Containing emulsions, dispersions, or solutions, Liposomes, Coronaviridae, e.g. avian infectious bronchitis virus, the drawings include the following: E. coli codon optimized nucleic, vector map of suicide vector, Salmonella Vectored Vaccines Against Chlamydia, vector map of suicide vector, numbered 12/999,246 (application), the patent is illustrated by 58 drawings, the application was examined by Rodney P. Swartz (1645 USPTO department), 23 claims comprise the protection scope, 22 figures depict the invention details, the recorded applicant's name is Lacy Michael Joseph, the applicant's state - MD, city - Gaithersburg, the primary classification Salmonella has been designated to the document, the grant number is 08703153 (publication number), the recorded inventor's name is Telfer Jonathan Lewis, the patent was granted on Apr. 22, 2014, particularly claims an attenuated Salmonella microorganism comprising i) an attenuating…, the claim number 1 is selected as exemplary.

Invention classification information

The invention is classified under Salmonella, Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, Gene therapy, In Vivo Diagnosis or in Vivo Testing, Salmonella, Shigella, Preparations for testing in vivo, Antigen, Epitope, or Other Immunospecific Immunoeffector, Bacterium or component thereof or substance produced by said bacterium, Genetically modified micro-organism, cell, or virus, Testing efficacy or toxicity of a compound or composition. The designated search classifications include Bacterium or component thereof or substance produced by said bacterium, In Vivo Diagnosis or in Vivo Testing, Testing efficacy or toxicity of a compound or composition, Salmonella, Antigen, Epitope, or Other Immunospecific Immunoeffector, Genetically modified micro-organism, cell, or virus.

Patent details
Publication number 08703153
Publication date Apr. 22, 2014
Kind code B2
Application number 12/999,246
Application date Jun. 16, 2009
Application type U
Application series code 12
Int. pub. country WO
Int. pub. number WO2009/158240
Int. publication Dec. 30, 2009
Int. filing country WO
Int. filing PCT/US2009/047542
Filed internationally Jun. 16, 2009
National stage date Jul. 20, 2011
National classification 424/258.1
Total number of claims 23
Exemplary claims 1
Number of drawings 58
Number of figures 22
More similar inventions

Medical Devices Having Polymeric Nanoporous Coatings for Controlled Therapeutic Agent Delivery and a Nonpolymeric Macroporous Protective Layer (US08734829, May 27, 2014 / 12/703,946, Feb. 11, 2010, Surgical implant or material), Jan Weber / Boston Scientific Scimed, Inc. (Maple Grove, US)

Method for Identification, Isolation and Production of Antigens to a Specific Pathogen (US08715688, May 6, 2014 / 13/613,761, Sept. 13, 2012, Disclosed amino acid sequence derived from bacterium), Thomas Weichhart et al. / Valneva Austria GmbH (Vienna, AT)

Vaccinia Virus Expression Vector for Selective Replication in a Tumor Cell and Introduction of Exogenous Nucleotide Sequence Into a Tumor Cell (US08506947, Aug. 13, 2013 / 11/707,453, Feb. 16, 2007, Whole Live Micro-Organism, Cell, or Virus Containing), Bernard Moss et al. / The United States of America as Represented by the Secretary of the Department of Health and Human Services (Washington, US)

Also viewed with this patent

Compositions of Polymeric Myrcene (US08722105, May 13, 2014 / 13/254,380, March 4, 2010, Plant Material or Plant Extract of Undetermined Constitution as Active Ingredient), Zadik Hazan et al.

1 H -[1, 2, 3] Triazole Substituted Amino Acids and Uses Thereof (US08722014, May 13, 2014 / 12/772,760, May 3, 2010, In Vivo Diagnosis or in Vivo Testing), Jonathan McConathy et al. / Washington University (Saint Louis, US)

Dosage Form for Insertion Into the Mouth (US08715715, May 6, 2014 / 12/608,445, Oct. 29, 2009, Mouth), Zheng Wang et al. / NAL Pharmaceuticals Ltd. (Causeway Bay, HK)

New documents
  • Process for the Production of the Actinobacillus Pleuropneumoniae Toxins APXI or APXIII in a Liquid Culture Medium Under Supply of Air Enriched in Carbon Dioxide
  • Method for Manufacturing Nonvolatile Memory Device
  • Supply Chain Demand Satisfaction
  • Supply-Line Management Device
  • Storage Control Device and Method for Managing Snapshot